Therapeutic Area
Iron Deficiency in Heart Failure Clinical Trials — Amavita Research
Cardiovascular trial site for iron deficiency in heart failure, conducted at amavita Heart and Vascular Health® in North Miami Beach, FL.
Iron deficiency is present in up to 50% of chronic heart failure patients, even without anemia, and is independently associated with reduced exercise capacity and worse outcomes. IV iron-replacement protocols continue to generate Phase 3 data on cardiovascular outcomes and quality of life. Here is what Amavita Research is currently running in this space.
Active trials at Amavita Research
- P-Monofer-CHF-02 — Ferric Derisomaltose
Sponsor: Pharmacosmos · Phase 3
Phase 3 evaluation of intravenous ferric derisomaltose (Monofer) in patients with chronic heart failure and iron deficiency.
Principal Investigators in this area
Why Amavita Research for iron deficiency in heart failure trials
- Heart failure patient cohort already engaged through the parent cardiology practice — both HFrEF and HFpEF.
- On-site IV infusion suite for protocol-defined IV iron dosing.
- Same-day venous draws for ferritin, TSAT, NT-proBNP, hemoglobin.
- Cardiology and internal-medicine co-management for iron-deficiency workup and follow-up.
- Active enrollment on Phase 3 P-Monofer-CHF-02 (Pharmacosmos ferric derisomaltose).
Think you might be eligible for a iron deficiency in heart failure trial?
Call (786) 703-5941 or use the patient contact form — initial screening is free and takes about 15 minutes.